<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625469</url>
  </required_header>
  <id_info>
    <org_study_id>IPF/PAH</org_study_id>
    <nct_id>NCT00625469</nct_id>
  </id_info>
  <brief_title>Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan</brief_title>
  <official_title>Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is
      a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently
      there is no significant data to support the use of pulmonary vasodilators for PAH in the
      setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH
      either at rest or during exercise. The study hypothesis is that bosentan may improve
      morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or
      exercise PAH.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>monthly assessement until date of lung transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>right heart catheterization hemodynamics</measure>
    <time_frame>variable based on time between listing and actual lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemokine peripheral blood analysis</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with resting or exercise induced PAH receive bosentan in a randomized open label fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with resting or exercise PAH get randomized to receive no specific therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with no evidence of either resting or exercise PAH receive no intervention but are followed until lung transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>62.5mg orally bid for first month, followed by 125mg bid thereafter</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No specific intervention</intervention_name>
    <description>No specific intervention</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No specific intervention</intervention_name>
    <description>No specific intervention</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Pulmonary Fibrosis referred for lung transplantation

          -  Minimum 50 meter 6 minute walk distance

          -  No significant underlying liver disease

        Exclusion Criteria:

          -  Significant liver disease or cirrhosis

          -  non ambulatory

          -  previous adverse reaction/allergy to Bosentan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajan Saggar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaela Dyke</last_name>
    <phone>310-825-5635</phone>
    <email>mdyke@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rajan Saggar, MD</last_name>
    <phone>310-825-5635</phone>
    <email>rsaggar@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David Geffen School of Medicine UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1690</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Dyke</last_name>
      <phone>310-825-5635</phone>
      <email>mdyke@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1690</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajan Saggar, M.D.</last_name>
      <phone>310-825-5635</phone>
      <email>rsaggar@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michaela Dyke</last_name>
      <phone>310-825-5635</phone>
      <email>mdyke@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rajan Saggar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David J Ross, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Belperio, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph P Lynch, III, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abbas Ardehali, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajeev Saggar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Zisman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <lastchanged_date>February 19, 2008</lastchanged_date>
  <firstreceived_date>February 19, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Rajan Saggar</name_title>
    <organization>David Geffen School of Medicine UCLA</organization>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>idiopathic pulmonary fibrosis</keyword>
  <keyword>bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
